Suven Pharmaceuticals to acquire controlling stake in NJ Bio

07 Dec 2024 Evaluate

Suven Pharmaceuticals is all set to acquire a controlling stake in NJ Bio Inc. (NJ Bio) with an investment of $64.4 million. Based in Princeton, NJ Bio is a premier ADC/XDC-focused CRDMO offering cutting-edge solutions across the ADC value chain.

This acquisition positions the company as a key player in one of the fastest growing segments of the Pharma CDMO landscape and it also extends the company’s current ADC offering with expertise across payload chemistry, payload-linker synthesis, bioconjugation, and AD specific analytical platform. The transaction is expected to close before the end of December 2024.

Suven Pharmaceuticals is India’s leading technology-focused CDMO, offering integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators.


Cohance Lifesciences Share Price

521.50 -2.00 (-0.38%)
02-Jan-2026 10:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1725.70
Dr. Reddys Lab 1243.00
Cipla 1506.85
Zydus Lifesciences 914.25
Lupin 2107.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×